CA-NEXON-AMERICA
17.11.2022 23:32:40 CET | Business Wire | Press release
Mabinogi, Nexon’s free-to-play fantasy MMORPG, begins the winter season with two meaningful events. Entitled “NEXT,” these two-part game updates include overhauled character growth, faster and more convenient leveling, plus revised tutorials and UI improvements during November, and the introduction of Arcana talents in December!
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221117006144/en/
Mabinogi, Nexon America's fantasy life MMORPG (Graphic: Business Wire)
Blaanid, the eager Memory Spirit, has prepared a new tutorial for all Milletians, making leveling and questing in Mabinogi faster overall! And Memoir Quests have been changed to now reward you for completing Generation quests. In Mabinogi's Masterpiece Update, Original Generation 1-3 Questline has been revamped to provide a friendly experience for new players as well as the ability to replay the quests for existing players. Mabinogi players new and old will find the starting experience even more user friendly! These updates, along with other elements such as Dan Advancement test improvements, and balance changes to Renown, Grandmaster, and Crusader skills are designed to drastically improve the early to mid-game leveling experience for all Milletians.
Memoir Rewards
-
Comfortable Growth - The perfect path to growth is Blaanid’s Brave Boost, which will grant you:
- Skills trained by Talent
- Upgraded and Reforged Memorial weapons
- Pet & Doll Bag Support
- and more!
-
Essential Skills & Benefits - Blaanid prepared even more gifts for new Milletians!
-
Your stats are increased as each Memoir Book is completed.
- Recall Book Stage 1~4
- Movement Speed +2%~8%
- All Stats +1~4
- Additional +1~4 AP at Rebirth!
-
Your stats are increased as each Memoir Book is completed.
Memorial Link
-
You can obtain this skill by completing the 2nd Memoir Book in Blaanid’s Brave Boost quests!
- Skill allows a soul connection with pets
- Pets can be used to draw enemy aggro
- As pets increase in level and skill, pets and player Defense and Protection stats increase proportionally
In addition to the above improvements, Quests have been reorganized, only displaying essential quests now, and skill training has also been improved - less training points are required and more EXP is earned to quickly achieve high ranked skills. Lastly, Mabinogi has removed CP Training, meaning monster levels are no longer relevant for your training requirements. Other changes, such as teleporting to Moon Gate and Mana Tunnels, were improved in this update to make it more convenient for new and returning players to traverse the world map.
In part two of the “NEXT” update coming in December, Mabinogi unveils a new pair of Hybrid Talents, merging two talent styles into a single devastating package! Get ready to experience the almighty power of the Elemental Knight or the soulful skill of the Harmonic Saint when the Arcana update arrives later in December!
These reasons, and many more, are why your “NEXT” MMORPG should be Mabinogi!
For more information on Mabinogi, visit the official website and follow @MabiOfficial on Twitter for the latest updates.
Assets: Image
Social Media: Facebook / Twitter / Instagram / Twitch / YouTube / Discord
About Mabinogi http://mabinogi.nexon.net/
Released in 2008, Mabinogi is an immersive free-to-play MMORPG world where mystical adventures await. Create anime-inspired heroes with thousands of customization options, such as hairstyles, facial features and outfits. Select from dozens of talents ranging from professional gunslingers and archers to musicians, tailors and cooks. Players can enjoy the game on their own terms, taking the perilous path of an adventurer or build a thriving business using unique trade skills.
About Nexon America Inc. https://www.nexon.com/
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221117006144/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
